Partners & Licenses Market advantage In Canada, melatonin is regulated as a Natural Health Product and requires a product license to be allowed on the market. Circa Dia obtained a product license for Ninotalem" in November 2006. The quality dossier meets all requirements for a melatonin-containing product to be commercialized in Canada. Ninotalem" is indicated for sleep disorders and jet-lag in adults and will become available without prescription. Compared to existing brands of melatonin products, Ninotalem" stands out because of its high quality and consistency and its proven track record in several clinical studies. Building on the success of clinical trials with Ninotalem" in children diagnosed with ADHD and in neurologically multiple disabled children, Circa Dia feels that Ninotalem"  may become the drug of choice to treat sleep disorders in these groups. Partnering and Licensing opportunities   Marketing, sales, distribution To develop the Canadian market for Ninotalem" and to expand to other countries and regions, Circa Dia is seeking corporate alliances related to marketing, sales and distribution support. Development of Ninotalem" for other indications Circa Dia is interested in scientific partnerships with academic research groups and hospitals to further develop Ninotalem" for children and adults who suffer from sleeping disorders caused by ADHD or the use of associated medication.   Development of novel melatonin-based drugs To employ Circa Dia"s IP portfolio, the company aims to establish corporate and scientific alliances to develop new melatonin-based drugs for various indications.   Licensing the NHPD Marketing Approval of Ninotalem" Parties interested in exploiting the NHPD Marketing Approval of Ninotalem" for the Canadian market should also contact Circa Dia. Licensing is certainly a possibility.